For example, erythematous patches, papules, and plaques have been reported in an estrogen and progesterone receptor-positive BC patient receiving anastrozole, with a median onset of 2 months (Sonke et al., 2018)
Regular medical follow-up is important during treatment to evaluate the efficacy and safety of the medication
PMID 37255827
Source: Employer Benefit Research Institute April 16, 2026 GLP-1 medications for obesity carry a well-documented discontinuation problem, and stopping them typically means regaining weight and the return of cardiometabolic risk factors
Musso G, Saba F, Cassader M, Gambino R
Most people start to see some changes in weight after the first month